TY - JOUR
T1 - Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors
AU - Caocci, Giovanni
AU - Mulas, Olga
AU - Annunziata, Mario
AU - Luciano, Luigiana
AU - Abruzzese, Elisabetta
AU - Bonifacio, Massimiliano
AU - Orlandi, Ester Maria
AU - Albano, Francesco
AU - Galimberti, Sara
AU - Iurlo, Alessandra
AU - Pregno, Patrizia
AU - Sgherza, Nicola
AU - Martino, Bruno
AU - Binotto, Gianni
AU - Castagnetti, Fausto
AU - Gozzini, Antonella
AU - Bocchia, Monica
AU - Fozza, Claudio
AU - Stagno, Fabio
AU - Simula, Maria Pina
AU - De Gregorio, Fiorenza
AU - Trawinska, Malgorzata Monika
AU - Scaffidi, Luigi
AU - Elena, Chiara
AU - Attolico, Imma
AU - Baratè, Claudia
AU - Cattaneo, Daniele
AU - Pirillo, Francesca
AU - Gugliotta, Gabriele
AU - Sicuranza, Anna
AU - Molica, Matteo
AU - La Nasa, Giorgio
AU - Foà, Robin
AU - Breccia, Massimo
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background: Limited information is available regarding the rate of long-term cardiovascular (CV) mortality in chronic myeloid leukaemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (2ndG/3rdG TKIs) in the real-life practice. Methods: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib. Results: The 15-year CV-mortality free survival was 93 ± 2.8%. Age ≥65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control. Conclusion. Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered.
AB - Background: Limited information is available regarding the rate of long-term cardiovascular (CV) mortality in chronic myeloid leukaemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (2ndG/3rdG TKIs) in the real-life practice. Methods: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib. Results: The 15-year CV-mortality free survival was 93 ± 2.8%. Age ≥65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control. Conclusion. Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered.
KW - a
KW - Cardiovascular toxicity
KW - Chronic myeloid leuk
KW - emia
KW - Ischemic heart disease
KW - TKI
UR - http://www.scopus.com/inward/record.url?scp=85075386674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075386674&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2019.10.036
DO - 10.1016/j.ijcard.2019.10.036
M3 - Article
C2 - 31711851
AN - SCOPUS:85075386674
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
ER -